Tumor Suppressors p53 and TGFβ Converge to Regulate the Alpha-Fetoprotein Oncodevelopmental Tumor Marker

2008 ◽  
pp. 309-320 ◽  
Author(s):  
Deepti S. Wilkinson ◽  
Michelle Craig Barton
Keyword(s):  
Tumor Marker ◽  
Tumor Suppressors ◽  
Alpha Fetoprotein

Biofunctionalized dendritic polyaniline nanofiber for in situ amplified glucometer-based enzyme immunoassay of tumor marker

2015 ◽  
Vol 7 (5) ◽  
pp. 1843-1848 ◽  
Author(s):  
Sheng Wu ◽  
Jinsuo Chen ◽  
Yujian Tian ◽  
Xiaoming Tang ◽  
Wei Li ◽  
...  
Keyword(s):  
Signal Transduction ◽  
Tumor Marker ◽  
Enzyme Immunoassay ◽  
Alpha Fetoprotein ◽  
Sensitive Detection ◽  
Polyaniline Nanofibers ◽  
Polyaniline Nanofiber

A new glucometer-based enzyme immunoassay was developed for the sensitive detection of alpha-fetoprotein using biofunctional dendritic polyaniline nanofibers as the signal-transduction tag.

scholarly journals Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Johannes C. Melms ◽  
Rohit Thummalapalli ◽  
Kristin Shaw ◽  
Huihui Ye ◽  
Leo Tsai ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Urothelial Cancer ◽  
Alpha Fetoprotein ◽  
Lesion Mimic

Lens Culinaris Agglutinin-reactive Fraction of Alpha-fetoprotein as a Tumor Marker in a Patient With Nonseminomatous Germ Cell Tumor With Normal Alpha-fetoprotein Level

2020 ◽  
Vol 18 (3) ◽  
pp. e309-e311 ◽  
Author(s):  
Hironori Sugiyama ◽  
Hideki Takeshita ◽  
Kojiro Tachibana ◽  
Shunsuke Hiranuma ◽  
Daisuke Takagi ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Marker ◽  
Germ Cell Tumor ◽  
Lens Culinaris ◽  
Cell Tumor ◽  
Alpha Fetoprotein ◽  
Lens Culinaris Agglutinin ◽  
Nonseminomatous Germ Cell Tumor

scholarly journals Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?

2019 ◽  
Vol 8 (10) ◽  
pp. 1736 ◽  
Author(s):  
Chao-Wei Lee ◽  
Hsin-I Tsai ◽  
Wei-Chen Lee ◽  
Shu-Wei Huang ◽  
Cheng-Yu Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Marker ◽  
Tumor Markers ◽  
Cox Regression ◽  
Hepatitis Virus ◽  
Significant Risk ◽  
Disease Free Survival ◽  
Alpha Fetoprotein ◽  
Virus Infections ◽  
Preoperative Serum

Introduction: serum alpha-fetoprotein (AFP) was routinely employed as a tumor marker for screening, diagnosis, and treatment follow-up of hepatocellular carcinoma (HCC). However, a substantial proportion of HCC patients had normal AFP level even at an advanced disease status. Few studies to date had tried to explore the nature and behavior of this normal AFP HCC (N-HCC). The purpose of this study was to investigate the clinicopathological characteristics and survival outcome of N-HCC after operation. In addition, potential tumor markers for N-HCC were also sought in an attempt to augment diagnostic ability. Methods: between 2005 and 2015, patients with hepatocellular carcinoma who were treated with hepatectomy in Chang Gung Memorial Hospital Linkou branch were divided into two groups according to their preoperative serum AFP level (<15 ng/mL: NHCC; ≥15 ng/mL: abnormal AFP HCC (A-HCC)). Patient demographic data and clinicopathological variables were collected. Kaplan–Meier and Cox regression multivariate analyses were performed to identify significant risk factors for disease-free survival (DFS) and overall survival (OS) for N-HCC. ELISA and immunohistochemical (IHC) studies were employed to determine the diagnostic accuracy of various tumor markers. Results: a total of 1616 patients (78% male) who underwent liver resection for HCC were included in this study. Of them, 761 patients (47.1%) were N-HCC. N-HCC patients were significantly older with more comorbidities and less hepatitis virus infections. Furthermore, N-HCC had fewer early recurrences (49.6% vs. 60.8%, p < 0.001) and better DFS (44.6 months vs. 23.6 months, p < 0.001) and OS (94.5 months vs. 81.7 months, p < 0.001). Both ELISA and IHC studies demonstrated that glypican-3 (GPC3) would be a promising diagnostic tumor marker for N-HCC. Conclusion: N-HCC patients were significantly older and had less hepatitis virus infections or cirrhosis. Their tumors tended to be smaller, less vascular invaded, and well-differentiated. The carcinogenesis of N-HCC may thus not be identical to that of typical HCC. GPC3 would be a promising tumor marker for diagnosing N-HCC. Further study is warranted to validate our findings.

scholarly journals On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir

Hepatology ◽  
2014 ◽  
Vol 59 (3) ◽  
pp. 986-995 ◽  
Author(s):  
Grace L.H. Wong ◽  
Henry L.Y. Chan ◽  
Yee-Kit Tse ◽  
Hoi-Yun Chan ◽  
Chi-Hang Tse ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Tumor Marker ◽  
Chronic Hepatitis B ◽  
Alpha Fetoprotein ◽  
Specific Tumor ◽  
Specific Tumor Marker

Application of Des-γ-Carboxy Prothrombin as a Complementary Tumor Marker with Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma

1989 ◽  
Vol 24 (1) ◽  
pp. 47-52 ◽  
Author(s):  
C. H. Ho ◽  
S. D. Lee ◽  
H. T. Chang ◽  
J. C. Wu ◽  
Y. T. Tsai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Marker ◽  
Alpha Fetoprotein

Is it time now to stop searching for other tumor markers for HCC apart from alpha-fetoprotein?

2021 ◽  
Vol 4 (1) ◽  
pp. 26-28
Author(s):  
Ahmed Esmaiel
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Alpha Fetoprotein ◽  
Diagnosis And Prognosis ◽  
Standard Marker

It’s a dilemma; does AFP still a standard marker in the diagnosis and prognosis of HCC or do we need another marker? Until now, no other tumor marker showed promising results in comparison to alpha-fetoprotein.

scholarly journals Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies

2008 ◽  
Vol 12 (6) ◽  
pp. e71-e76 ◽  
Author(s):  
Kailapuri G. Murugavel ◽  
S. Mathews ◽  
V. Jayanthi ◽  
Esaki Muthu Shankar ◽  
R. Hari ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Marker ◽  
Alpha Fetoprotein ◽  
South Indian

scholarly journals Inappropriate practice in tumor marker requests at a university hospital in Western Saudi Arabia: A 3-year retrospective study

2020 ◽  
Vol 35 (4) ◽  
pp. 35-43
Author(s):  
Jamil A. Al-Mughales ◽  
Mahmood Shaheen Alahwal
Keyword(s):  
Tumor Marker ◽  
Carcinoembryonic Antigen ◽  
Prostate Specific Antigen ◽  
Clinical Picture ◽  
Specific Antigen ◽  
Alpha Fetoprotein ◽  
University Hospital ◽  
Prescribing Pattern ◽  
Inappropriate Use ◽  
Total Prostate Specific Antigen

Objectives: This study assessed the level of appropriateness of tumor marker requests in a teaching hospital and estimated the financial cost associated with inappropriate use. Methods: A retrospective review of patients’ electronic records was conducted over a 3-year period (2015–2017) for tumor marker requests, including carcinoembryonic antigen, alpha-fetoprotein, cancer antigen (CA)15-3, CA125, CA19-9, and total and free prostate-specific antigen (PSA and fPSA), along with the associated clinical data that motivated the requests. Inappropriate use was defined as tumor marker requests without any relevant clinical picture. Costs due to inappropriate tumor marker requests were estimated based on the unit costs applied in the institution. Results: A total of 7128 patients had at least one tumor marker request between 2015 and 2017. The clinical picture that motivated tumor marker requests was absent in 71.5%, while 12.9% of the requests were associated with a malignancy. The most frequent prescribing pattern was total prostate-specific antigen alone (2128; 29.9%), followed by alpha-fetoprotein alone (1185; 16.6%), and carcinoembryonic antigen alone (506; 7.1%). Year-over-year analysis revealed an increasing tendency in requesting carcinoembryonic antigen and CA15-3. The rate of inappropriate use varied by tumor marker and ranged between 56.4% for fPSA and 86.8% for total prostate-specific antigen. The overall costs due to inappropriate tumor marker requests were estimated at $2,785,493 over the 3 years, representing an average of $0.93 million per year. Conclusion: Inappropriate use of tumor marker requests is a major issue regarding its high prevalence and the considerable associated costs. The role of laboratories in the management of tumor marker requests should be emphasized.

Sign in / Sign up

Export Citation Format

Share Document